California Institute for Regenerative Medicine (CIRM)   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Oakland CA United States (2004)

Organization Overview

First Clinical Trial
2017
NCT03240861
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

California Institute for Regenerative Medicine (CIRM)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia, Sickle Cell (Phase 1)

Cystinosis (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Lymphoma (Phase 1)

Lysosomal Storage Diseases (Phase 2)

Multiple Myeloma (Phase 1)

Retinitis (Phase 2)

Retinitis Pigmentosa (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 26